Live Analyst Rating Changes 42254 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Debanjana Chatterjee
JONE

Debanjana Chatterjee

JonesTrading
Wall Street Analyst
★★☆☆☆
#2406
on 13Foresight · ranked by our own returns
40%
Success Rate
-3.1%
Average Return
29 of 72 calls profitable · +21.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 40% of Debanjana Chatterjee's ratings turned a profit when each position was held for 1 year — averaging -3.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

158 Buy 10 Hold 0 Sell
Debanjana's Stock Coverage 17 ratings · 2026-10-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CTNM
Contineum Therapeutics, Inc. Class A
 Oct 14, 2026 BUY Strong Buy
+166.8% avg upside
9 analysts
$30.00
275.04% Upside
 -2.9% ·
EYPT
EyePoint Pharmaceuticals
 Oct 07, 2026 BUY Strong Buy
+655.5% avg upside
21 analysts
$20.00
534.91% Upside
 +2.4% ·
IRD
Opus Genetics
 Oct 05, 2026 BUY Strong Buy
+190.8% avg upside
25 analysts
$17.00
322.88% Upside
 +6.2% ·
SYRE
Spyre Therapeutics
 Oct 01, 2026 BUY Strong Buy
+19.7% avg upside
25 analysts
$130.00
62.33% Upside
 -12.6% ·
ARMP
Armata Pharmaceuticals
 Sep 27, 2026 BUY Strong Buy
+373.6% avg upside
4 analysts
$20.00
538.99% Upside
 -4.0% ·
SGMT
Sagimet Biosciences, Inc. Class A
 Sep 27, 2026 BUY Strong Buy
+272.8% avg upside
17 analysts
$31.00
276.21% Upside
 -24.1% ·
ABCL
AbCellera Biologics
 Sep 27, 2026 BUY Strong Buy
+27.6% avg upside
17 analysts
$25.00
95.76% Upside
 -11.1% ·
TVRD
Tvardi Therapeutics
 Sep 15, 2026 BUY Strong Buy
+1588.2% avg upside
24 analysts
$10.00
843.40% Upside
 -39.2% ·
HYFT
MindWalk Holdings
 Sep 15, 2026 BUY Strong Buy
+213.9% avg upside
3 analysts
$5.00
262.27% Upside
 +29.4% ·
PHVS
Pharvaris
 Sep 09, 2026 BUY Strong Buy
+86.3% avg upside
15 analysts
$65.00
117.98% Upside
 -17.6% ·
ATHE
Alterity Therapeutics
 Aug 28, 2026 BUY Strong Buy
+262.0% avg upside
8 analysts
$16.00
483.99% Upside
 -39.7% ·
EVAX
Evaxion Biotech
 Aug 21, 2026 BUY Strong Buy
+348.9% avg upside
6 analysts
$10.00
258.36% Upside
 -7.2% ·
NTLA
Intellia Therapeutics
 Aug 14, 2026 BUY Buy
+210.8% avg upside
39 analysts
$29.00
146.17% Upside
 -4.0% ·
TRVI
Trevi Therapeutics
 Aug 13, 2026 BUY Strong Buy
+95.4% avg upside
18 analysts
$28.00
129.75% Upside
 -33.3% ·
ABSI
AbSci
 Aug 12, 2026 BUY Strong Buy
+44.0% avg upside
19 analysts
$13.00
45.54% Upside
 +7.0% ·
SION
Sionna Therapeutics, Inc.
 Aug 10, 2026 HOLD Buy
+392.5% avg upside
12 analysts
$63.00
1427.33% Upside
 -2.7% ·
CYVNY
Ceryvyn Therapeutics Limited
 May 22, 2026 HOLD Hold
+32367.5% avg upside
7 analysts
 — -34.3% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Debanjana Chatterjee — Frequently Asked Questions
How accurate are Debanjana Chatterjee's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Debanjana's ratings were profitable over a one-year hold, with an average return of -2.9% per rating, or +21.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Debanjana ranked on 13Foresight?
Debanjana Chatterjee is currently ranked #2406 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Debanjana cover?
Debanjana most recently has ratings on CTNM, EYPT, IRD, SYRE, ARMP, SGMT, ABCL, TVRD, HYFT, PHVS, ATHE, EVAX and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.